PUBLIC COMPANY
save$TEVATEVA PHARMACEUTICAL INDUSTRIES LTD
$TEVA39.53+0.56%Tel Aviv, ILupdated 10h ago
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
community read0 votes
pipeline
6
marketed
1
phase 3
1
catalysts ytd
10
approvals ytd
4
recalls ytd
3
Pipeline(6)
pipeline depth6 products
3Phase 21Phase 31Marketed1pre_registration
Marketed
omacetaxine mepesuccinate
Myelodysplastic Syndrome (Preleukemia)
Phase 3duvakitug
Crohn's Disease (Regional Enteritis)
Phase 2CEP-11981
Pancreatic Cancer
Vascular endothelial growth factor receptorAngiopoietin-1 receptor
Phase 2TEV-408
Celiac Disease
Phase 2emrusolmin
Multiple System Atrophy (Multi-System Degeneration)
pre_registrationolanzapine ER
Schizophrenia
D2-like dopamine receptor5-hydroxytryptamine receptor 2C
Upcoming
Recent(90d)
view all catalysts →🐶 Hiring Signal
next earnings Nov 4, 2026
News
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Lilly, Foghorn part ways; Wave’s FDA-approved plansThe pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.biopharma_dive · 2d ago
- Chutes & Ladders—Longtime Takeda R&D chief to depart next JuneTakeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.fiercebiotech · 23d ago
- Teva says gluten challenge study succeeds in celiac diseaseA single injection of an experimental antibody significantly reduced intestinal damage among people with celiac disease who then ate gluten daily, Teva Pharmaceuticals said Wednesday. The Israeli d…endpoints · 1mo ago
- Teva claims success in celiac study; BioMarin, Ascendis settle patent disputeTeva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.biopharma_dive · 1mo ago
- Teva autoimmune antibody notches ph. 2 win in celiac diseaseTeva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s anti-interleukin-15 antibody scored a midstage win in celiac disease.fiercebiotech · 1mo ago
- Mid-cap biotechs join Trump’s latest round of drug pricing dealsFocused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.biopharma_dive · 1mo ago
- STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and moreNovartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug. Read the latest pharma headlines in today's…stat · 1mo ago
- 9 midsize drugmakers climb aboard Trump’s MFN trainAstellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program…biospace · 1mo ago
- STAT+: Trump strikes nine more deals with drugmakers to lower pricesPresident Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.stat · 1mo ago
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that